Vaccines-2013 - OMICS Group

Recommendations

Info

Fisseha Walle et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USACoverage and factors associated with tetanus toxoid vaccination among private collegestudents, Bahirdar, EthiopiaFisseha Walle 1 and Mekibib Kassa 21Regional Health Research Laboratory Center, Ethiopia2Alkan University College, EthiopiaBackground: The purpose of this study was to estimate the coverage and determine the factors associated with tetanus toxoidvaccination status among female’s private colleges students in Bahir Dar, Ethiopia.Methods: A Cross-sectional study was conducted in Bahir Dar, from September 15 to October 17, 2011. A total of 239 femalesof reproductive age students (17‒45) years were selected from Colleges in Bahir Dar through random sampling. A pre-testedstructured questionnaire was administered to students and the data was analyzed using SPSS version 18 and associated factorsassessed using logistic regression.Results: The coverage of tetanus toxoid immunization among private college students were 31.5%. Degree students were aboutfour times more likely to have had tetanus toxoid vaccine utilization than diploma students (AOR=4, 95%CI=3.16, 9.87). Maritalstatus was one of the independent predictors for tetanus toxoid vaccine. Married women were found to have 3 times more likely tobe engaged tetanus toxoid vaccine utilization than single (AOR=3, 95%CI=2.91, 8.67). Besides, the odds of having tetanus toxoidvaccine utilization among private college students who had family income earns
Deryabin P.N. et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAThe influence interleukin-1 to a protective and immunogenic activity living plague vaccineDeryabin P.N, Ponomaryova T.S, Karalnik B.V, Tugambayev T.I, Denisova T.G, Atshabar B.B and Zakaryan S.BKazakh Scientific Center for Qarantine and Zoonotic Diseases, KazakhstanPreviously, our experiments showed that polyoxidonium possessing of adjuvant and immunomodulatory effects increases thea protective and immunogenic activity living plague vaccine based on the strain Y. pestis EV (LPV) / PN Deryabin et al., 2012,Tatyana Ponomareva et al., 2010. On some models of infectious diseases show immunomodulatory effect of preparations on thebasis of the interleukin-1 (IL-1) / «Citokin» ltd., St. Petersburg, Russia./. To assess the effect of IL-1 on the efficiency LPV we used"Betaleukin" (recombinant IL-1β, which was to be produced using genetic engineering technology).We evaluated the influence on the efficiency of IL-1 live plague vaccine in experiments on guinea pigs (2 groups of 75animals). The experimental group of animals was vaccinated Y. pestis EV (100,000 microbial cells) with IL-1 (0.5 mg/ind.). Thecontrol group - only vaccine Y. pestis EV (100,000 microbial cells). At 21 days after immunization, both groups of animals wereinfected with a virulent strain of Y. pestis 231 in a dose of 200 DCI.In the experimental group within 14 days after infection of animal deaths were observed. All animals in this group weresacrificed at 14 days after infection, culture Y. pestis 231 is not selected. In the control group fell 50% of the animals. Survivinganimals were sacrificed at 14 days after infection, some animals there was an increase of culture Y. pestis 231 of the spleen.The titer of specific antibodies in the serum of animals of experimental group (before infection) was significantly higher (1:2000) than in the control group (1:80).Additionally influence of IL-1 on the immunogenicity LPV were studied in 8 rabbits immunized EV vaccine at 3 x 10 6bacterial cells in 0.5 ml of physiologically solution.t. Four rabbits were injected simultaneously Betaleukin (IL-1) at a dose of 0.5mg (experimental group), the other 4 rabbits with physiological solution in the same volume (the control group).Antigen-specific response was evaluated to detect antibodies to F1antigenu and lymphocyte with receptors to to the sameantigen (LfRF1). The use of IL-1 accelerated the appearance and disappearance of LfRF1, the maximum of of their content,reducing the amount of their maximum and total and also ensure earlier appearance of anti-F1 antibodies in rabbits that receivedIL-1. The findings suggest that the use of preparations by IL-1 accelerated the development of antigen-specific response toZHCHV early and effector phase.The study showed prospects of of application of preparations of IL-1 to increase the effectiveness living plague vaccine.BiographyDeryabin Pavel, born in 1956. In 1992 he defended his thesis for the degree of doctor of medical sciences, specialty "Allergology and Immunology",in 1994 he got the title-the professor. The author of more than 170 scientifi c papers, including more than 30 peer-reviewed journals. Has 14 patents.Head of the special training center regional training center on biosafety and biosecurity Kazakh Scientifi c Center for Qarantine and ZoonoticDiseases.572202@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 107
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105: Yurong Tan et al., J Vaccines Vacci
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?